Applied Biosystems/MDS Analytical Technologies Accelerates Productivity for Drug Development & Clinical Research With New Mas...
01 Juni 2009 - 1:30PM
Business Wire
Applied Biosystems, a division of Life Technologies Corporation
(NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS
Analytical Technologies, a business unit of MDS Inc. (TSX:MDS)
(NYSE:MDZ), today announced the launch of Cliquid� MPX�-2
high-throughput workflow, an end-to-end solution for mass
spectrometry users to accelerate productivity for pharmaceutical
and clinical research. The Cliquid MPX workflow integrates a new
software application with mass spectrometers, high-performance
liquid chromatography systems and auto-samplers to uniquely
increase throughput for faster results while in accordance with
Good Laboratory Practice (GLP) standards of regulated markets. This
can help bring new drugs to market more quickly.
The new Cliquid MPX solution addresses the need of
pharmaceutical companies and clinical researchers to improve the
productivity and efficiency of laboratory analysis. This solution
can as much as double the throughput of Applied Biosystems/MDS
Analytical Technologies QTRAP� and triple quadrupole mass
spectrometers, which are widely used to analyze high volumes of
samples. This increased speed enables scientists to more rapidly
collect critical data that affects decision-making for advancing a
drug candidate or conducting clinical studies.
The workflow is enabled by Cliquid MPX software, which allows
concurrent LC/MS/MS analysis of two streams into a single mass
spectrometer with either Cliquid Software or Analyst� Software.
This is an innovation in mass spectrometry to create a single point
of control for managing the complete workflow, which is supported
by Applied Biosystems Global Services. This enables laboratories to
increase throughput while achieving regulatory compliance by using
the audit and traceability functionality of Analyst Software,
providing the most efficient solution of its type within the
life-science industry.
Laura Lauman, President of Life Technologies Mass
Spectrometry Systems Division
�The pharmaceutical industry is under immense pressure to
accelerate drugs to market. We provide the innovative tools to
enable scientists to more rapidly conduct critical analyses and
advance new drug candidates through the development process. The
increased throughput of our industry-leading instruments, combined
with the ability to integrate with third-party components, enables
a unique, integrated workflow solution that will ultimately
increase speed to market for new drug candidates.�
Andy Boorn, President of MDS Analytical Technologies
�The Cliquid MPX workflow solution is the latest in a line of
innovative software releases from the Applied Biosystems/MDS
Analytical Technologies joint venture. This advancement enables an
end-to-end workflow to improve laboratory analysis, while
supporting the highest levels of regulatory compliance.�
Additional Resources
Overview of Cliquid Software
Overview of Analyst Software
Applied Biosystems/MDS Analytical Technologies mass
spectrometers: Overview of Applied Biosystems/MDS Analytical
Technologies systems
About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative
instrument systems to accelerate academic and clinical research,
drug discovery and development, pathogen detection and forensic DNA
analysis. Applied Biosystems, along with Invitrogen � a leading
provider of platform independent, essential life science
technologies for disease and drug research, bioproduction and
diagnostics � is part of Life Technologies. Applied Biosystems and
Invitrogen products are used in nearly every major laboratory in
the world. For more information, please visit:
www.appliedbiosystems.com and www.invitrogen.com.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global
biotechnology tools company dedicated to improving the human
condition. Our systems, consumables and services enable researchers
to accelerate scientific exploration, driving to discoveries and
developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to
advance personalized medicine, regenerative science, molecular
diagnostics, agricultural and environmental research, and 21st
century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence
in more than 100 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,600 patents and
exclusive licenses. Life Technologies was created by the
combination of Invitrogen Corporation and Applied Biosystems Inc.
For more information on how we are making a difference please visit
our website: www.lifetechnologies.com.
About MDS Analytical Technologies
MDS Analytical Technologies, a business unit of MDS Inc.
(TSX:MDS) (NYSE:MDZ), is focused on the research, design,
manufacture and marketing of state-of-the-art tools for
mass-spectrometry, drug discovery and bioresearch. MDS Analytical
Technologies� products are designed to help accelerate the complex
process of discovering and developing new drug compounds, and are
sold to research scientists around the world. The mass-spectrometer
product lines are also sold globally through joint ventures with
two of the world�s leading analytical instrumentation and
life-sciences companies, Life Technologies Corporation and
PerkinElmer, Inc. Find out more at www.mdssciex.com or
www.moleculardevices.com.
Life Technologies Safe Harbor Statement
This press release includes forward-looking statements about
Life Technologies� anticipated results that involve risks and
uncertainties. Some of the information contained in this press
release, including, but not limited to, statements as to industry
trends and Life Technologies� plans, objectives, expectations and
strategy for its business, contains forward-looking statements that
are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or
implied by such forward-looking statements. Any statements that are
not statements of historical fact are forward-looking statements.
When used, the words �believe,� �plan,� �intend,� �anticipate,�
�target,� �estimate,� �expect� and the like, and/or future tense or
conditional constructions (�will,� �may,� �could,� �should,� etc.),
or similar expressions, identify certain of these forward-looking
statements. Important factors which could cause actual results to
differ materially from those in the forward-looking statements are
detailed in filings made by�Life Technologies with the Securities
and Exchange Commission.�Life Technologies undertakes no obligation
to update or revise any such forward-looking statements to reflect
subsequent events or circumstances.
Copyright 2009. Life Technologies Corporation. All rights
reserved. Analyst, Cliquid and QTRAP are registered trademarks and
MPX is a trademark of Applied Biosystems/MDS Analytical
Technologies, a joint venture between Applied Biosystems LLC and
MDS Inc.
Mds (NYSE:MDZ)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Mds (NYSE:MDZ)
Historical Stock Chart
Von Jul 2023 bis Jul 2024